Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer

BACKGROUND AND PURPOSE: This single institution phase I trial determined the maximum tolerated dose (MTD) of concurrent vorinostat and capecitabine with radiation in non-metastatic pancreatic cancer. MATERIAL AND METHODS: Twenty-one patients received escalating doses of vorinostat (100–400 mg daily)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Radiother Oncol
Main Authors: Chan, Emily, Arlinghaus, Lori R., Cardin, Dana B., Goff, Laura, Berlin, Jordan D., Parikh, Alexander, Abramson, Richard G., Yankeelov, Thomas E., Hiebert, Scott, Merchant, Nipun, Bhaskara, Srividya, Chakravarthy, Anuradha Bapsi
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4961249/
https://ncbi.nlm.nih.gov/pubmed/27106554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2016.04.013
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki